Search
ivacaftor/tezacaftor
Indications:
- treatment of cystic fibrosis with CFTR Phe508del mutation
Dosage:
- ivacaftor 150 mg BID
- tezacaftor 100 mg QD
Adverse effects:
- shortness of breath
- upper respiratory tract infection
Mechanism of action:
- CFTR potentiator
General
pharmacologic combination
pulmonary agent
Database Correlations
PUBCHEM cid=72722243
References
- Taylor-Cousar JL, Munck A, McKone EF et al
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis
Homozygous for Phe508del.
N Engl J Med 2017; 377:2013-2023. Nov 23, 2017
PMID: 29099344 Free full text
http://www.nejm.org/doi/full/10.1056/NEJMoa1709846
- Rowe SM, Daines C, Ringshausen FC et al
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes
with Cystic Fibrosis.
N Engl J Med 2017; 377:2024-2035. Nov 23, 2017
PMID: 29099333 Free full text
http://www.nejm.org/doi/full/10.1056/NEJMoa1709847
Components
ivacaftor
tezacaftor